Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 5/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 2/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20122984 | 1.00 | DYRK1A (0.43) | DYRK1AHASPINACHEDYRK2MAOA | |
| SCHEMBL30664291 | 0.88 | DYRK1A (0.44) | DYRK1AHASPINACHEDYRK2MAOA | |
| SCHEMBL20123005 | 0.88 | DYRK1A (0.44) | DYRK1AHASPINACHEDYRK2MAOA | |
| SCHEMBL20123023 | 0.87 | DYRK1A (0.45) | DYRK1AHASPINACHEDYRK2MAOA | |
| SCHEMBL29756351 | 0.87 | DYRK1A (0.45) | DYRK1AHASPINACHEDYRK2MAOA | |
| SCHEMBL20122852 | 0.85 | DYRK1A (0.42) | DYRK1AHASPINACHEDYRK2MAOA | |
| SCHEMBL30664304 | 0.85 | DYRK1A (0.42) | DYRK1AHASPINACHEDYRK2MAOA | |
| SCHEMBL20122889 | 0.83 | DYRK1A (0.46) | DYRK1AHASPINACHEDYRK2MAOA | |
| SCHEMBL20122935 | 0.83 | DYRK1A (0.41) | DYRK1AHASPINDYRK2AAK1 | |
| SCHEMBL30664285 | 0.83 | DYRK1A (0.41) | DYRK1AHASPINDYRK2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2025-04-15 | — | — | US | disclosed |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | DYRK1A 493/4885HASPIN 2412/4885ACHE 2558/4885 |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | DYRK1A 493/4885HASPIN 2412/4885ACHE 2558/4885 |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | DYRK1A 493/4885HASPIN 2412/4885ACHE 2558/4885 |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | DYRK1A 498/4885HASPIN 2588/4885ACHE 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.